We are live on ! Find out more

Sight Sciences

SGHT

Market cap $445M

8.08 USD

-0.06

0.74%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

8.08

0.00

0%

1 day

-0.74%

5 days

-0.62%

1 month

-1.94%

3 months

61.28%

6 months

107.71%

Year to date

8.02%

1 year

136.26%

5 years

-68.41%

10 years

-75.88%

About: Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Employees: 186

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 18.2%

Neutral 72.7%

Negative 9.1%

Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

MENLO PARK, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform care and improve patients' lives, today announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the TearCare® System (TearCare) Indications for Use to state:

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences Q2 Earnings Call Highlights

Sight Sciences NASDAQ: SGHT reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.

Sight Sciences Q2 Earnings Call Highlights

Zacks Investment Research

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Sight Sciences Reports Second Quarter 2026 Financial Results

Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eyecare and improve patients' lives, today announced that Aetna, Inc.'s (Aetna) updated Glaucoma Surgery Policy for its commercial plans now recognizes the OMNI® Surgical System (OMNI) and the SION® Surgical Instrument (SION) as medically necessary for the treatment of mild-to-moderate open-angle glaucoma when specified clinical criteria are met, establishing coverage of Sight Sciences' interventional glaucoma technologies.

Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

New system expands the Company's leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation. New system expands the Company's leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation.

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

See News Rankings

Price charts implemented using Lightweight Charts™